Abbott Laboratories (ABT) Depreciation & Amortization (CF) (2009 - 2026)

Abbott Laboratories has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $381.0 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $381.0 million, up 13.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 10.13% YoY), and the FY2025 annual result was $1.4 billion, up 7.01% from the prior year.
• Depreciation & Amortization (CF) came in at $381.0 million for Q1 2026 at Abbott Laboratories, up from $370.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $381.0 million in Q1 2026 to a low of $302.0 million in Q2 2023.
• The 5-year median for Depreciation & Amortization (CF) is $332.0 million (2023), against an average of $334.5 million.
• Across the five-year window, Depreciation & Amortization (CF) slipped 26.82% in 2022 and climbed 13.39% in 2026, its largest moves.
• Abbott Laboratories' Depreciation & Amortization (CF) stood at $311.0 million in 2022, then advanced by 6.75% to $332.0 million in 2023, then rose by 3.01% to $342.0 million in 2024, then advanced by 8.19% to $370.0 million in 2025, then grew by 2.97% to $381.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $381.0 million (Q1 2026), $370.0 million (Q4 2025), and $371.0 million (Q3 2025), per Business Quant data.